Zuhier A Awan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4395368/publications.pdf

Version: 2024-02-01

73 papers

2,800 citations

186265
28
h-index

51 g-index

79 all docs

79 docs citations

79 times ranked

3998 citing authors

#	Article	lF	CITATIONS
1	Identifying significant genes and functionally enriched pathways in familial hypercholesterolemia using integrated gene co-expression network analysis. Saudi Journal of Biological Sciences, 2022, 29, 3287-3299.	3.8	4
2	Association between serum uric acid with diabetes and other biochemical markers. Journal of Family Medicine and Primary Care, 2022, 11, 1401.	0.9	6
3	Molecular profiling of melanocortin 4 receptor variants and agouti-related peptide interactions in morbid obese phenotype: a novel paradigm from molecular docking and dynamics simulations. Biologia (Poland), 2022, 77, 1481.	1.5	2
4	Identification of Novel and Known LDLR Variants Triggering Severe Familial Hypercholesterolemia in Saudi Families. Current Vascular Pharmacology, 2022, 20, 361-369.	1.7	1
5	Associations between body mass index, body composition and bone density in young adults: Findings from Saudi cohort. Journal of Radiation Research and Applied Sciences, 2022, 15, 268-274.	1.2	1
6	Identification and functional characterization of 2 Rare LDLR stop gain variants (p.C231* and p.R744*) in Saudi familial hypercholesterolemia patients. Panminerva Medica, 2022, , .	0.8	3
7	Effect of Altitude on Hemoglobin and Red Blood Cell Indices in Adults in Different Regions of Saudi Arabia. International Journal of General Medicine, 2022, Volume 15, 3559-3565.	1.8	4
8	Optimized 2-methoxyestradiol invasomes fortified with apamin: a promising approach for suppression of A549 lung cancer cells. Drug Delivery, 2022, 29, 1536-1548.	5.7	8
9	Isolated Neutropenia/Benign Ethnic Neutropenia: A Common Clinical and Laboratory Finding in Southern and Western Saudi Arabia. International Journal of General Medicine, 2021, Volume 14, 451-457.	1.8	3
10	Repurposing of Some Natural Product Isolates as SARS-COV-2 Main Protease Inhibitors via In Vitro Cell Free and Cell-Based Antiviral Assessments and Molecular Modeling Approaches. Pharmaceuticals, 2021, 14, 213.	3.8	45
11	Familial Hypercholesterolemia in the Arabian Gulf Region: Clinical results of the Gulf FH Registry. PLoS ONE, 2021, 16, e0251560.	2.5	17
12	Project-Based Learning Strategy for Teaching Molecular Biology: A Study of Students' Perceptions. Education in Medicine Journal, 2021, 13, 43-53.	0.4	2
13	Development of Polymer and Surfactant Based Naringenin Nanosuspension for Improvement of Stability, Antioxidant, and Antitumour Activity. Journal of Chemistry, 2020, 2020, 1-10.	1.9	7
14	<p>Optimized Nanostructured Lipid Carriers Integrated into In Situ Nasal Gel for Enhancing Brain Delivery of Flibanserin</p> . International Journal of Nanomedicine, 2020, Volume 15, 5253-5264.	6.7	28
15	Improvement initiative in LDL-C management in Saudi Arabia: A call to action. IJC Heart and Vasculature, 2020, 31, 100667.	1.1	7
16	The Prevalence of Isolated Neutropenia at High Altitude in Southern Saudi Arabia: Does Altitude Affect Leucocyte Count?. International Journal of General Medicine, 2020, Volume 13, 1373-1379.	1.8	8
17	Piceatannol-Loaded Emulsomes Exhibit Enhanced Cytostatic and Apoptotic Activities in Colon Cancer Cells. Antioxidants, 2020, 9, 419.	5.1	38
18	Molecular insights into the coding region mutations of lowâ€density lipoprotein receptor adaptor protein 1 (LDLRAP1) linked to familial hypercholesterolemia. Journal of Gene Medicine, 2020, 22, e3176.	2.8	12

#	Article	IF	CITATIONS
19	Spectral signal processing approaches for selective quantification of the recently FDA approved brand-new combination of Vaborbactam and Meropenem; for conformity assessment of bulk and batch release. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2020, 230, 118066.	3.9	1
20	Improved Analgesic and Anti-Inflammatory Effect of Diclofenac Sodium by Topical Nanoemulgel: Formulation Development— <i>In Vitro</i> and <i>In Vivo</i> Studies. Journal of Chemistry, 2020, 2020, 1-10.	1.9	26
21	Prevalence of Helicobacter pylori Infection and Diagnostic Methods in the Middle East and North Africa Region. Medicina (Lithuania), 2020, 56, 169.	2.0	13
22	Levels of soluble cell adhesion molecules in type 2 diabetes mellitus patients with macrovascular complications. Journal of International Medical Research, 2020, 48, 030006051989385.	1.0	13
23	Assessment of medical intern's knowledge, awareness and practice of familial hypercholesterolemia at academic institutes in Jeddah, Saudi Arabia. Lipids in Health and Disease, 2020, 19, 101.	3.0	4
24	Molecular design, synthesis and biological characterization of novel Resveratrol derivative as potential anticancer agent targeting NF-κB. Journal of Applied Biomedicine, 2020, 18, 8-17.	1.7	3
25	The genetic association study of TP53 polymorphisms in Saudi obese patients. Saudi Journal of Biological Sciences, 2019, 26, 1338-1343.	3.8	7
26	PCSK9 and inflammation: a review of experimental and clinical evidence. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 237-245.	3.0	104
27	Large-Scale Production of Bioactive Terrein by Aspergillus terreus Strain S020 Isolated from the Saudi Coast of the Red Sea. Biomolecules, 2019, 9, 480.	4.0	21
28	Identification of key regulatory genes connected to NF- $\hat{1}$ B family of proteins in visceral adipose tissues using gene expression and weighted protein interaction network. PLoS ONE, 2019, 14, e0214337.	2.5	23
29	Recently reported familial hypercholesterolemia-related mutations from cases in the Middle East and North Africa region. Current Opinion in Lipidology, 2019, 30, 88-93.	2.7	4
30	The Gulf Familial Hypercholesterolemia Registry (Gulf FH): Design, Rationale and Preliminary Results. Current Vascular Pharmacology, 2019, 18, 57-64.	1.7	23
31	Integrating an interprofessional education initiative: Evidence from King Abdulaziz University. Medical Teacher, 2018, 40, S15-S21.	1.8	3
32	Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics. Journal of Clinical Lipidology, 2018, 12, 1027-1038.	1.5	10
33	In Silico Approach to Investigate the Structural and Functional Attributes of Familial Hypercholesterolemia Variants Reported in the Saudi Population. Journal of Computational Biology, 2018, 25, 170-181.	1.6	4
34	Simplified Canadian Definition for Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2018, 34, 1210-1214.	1.7	62
35	Protein phenotype diagnosis of autosomal dominant calmodulin mutations causing irregular heart rhythms. Journal of Cellular Biochemistry, 2018, 119, 8233-8248.	2.6	14
36	Assisting the integration of social media in problem-based learning sessions in the Faculty of Medicine at King Abdulaziz University. Medical Teacher, 2018, 40, S37-S42.	1.8	11

#	Article	IF	Citations
37	Estrogen-associated severe hypertriglyceridemia with pancreatitis. Journal of Clinical Lipidology, 2017, 11, 297-300.	1.5	21
38	Aortic Calcification Progression in Heterozygote Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2017, 33, 658-665.	1.7	15
39	Thrombin activation of protein C requires prior processing by a liver proprotein convertase. Journal of Biological Chemistry, 2017, 292, 10564-10573.	3.4	10
40	The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation. Journal of Biological Chemistry, 2017, 292, 1573-1590.	3.4	30
41	Perinatal ciclosporin A exposure elicits sex-related cardiac dysfunction and inflammation in the rat progeny. Toxicology Letters, 2017, 281, 35-43.	0.8	10
42	The Spectrum of Familial Hypercholesterolemia (FH) in Saudi Arabia: Prime Time for Patient FH Registry. Open Cardiovascular Medicine Journal, 2017, 11, 66-75.	0.3	15
43	Interpreting the Mechanism of APOE (p.Leu167del) Mutation in the Incidence of Familial Hypercholesterolemia; An In-silico Approach. Open Cardiovascular Medicine Journal, 2017, 11, 84-93.	0.3	11
44	Dyslipidaemia in the Middle East: Current status and a call for action. Atherosclerosis, 2016, 252, 182-187.	0.8	37
45	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East. International Journal of Cardiology, 2016, 225, 268-283.	1.7	17
46	Reducing Vascular Calcification by Anti-IL- $\hat{1}^2$ Monoclonal Antibody in a Mouse Model of Familial Hypercholesterolemia. Angiology, 2016, 67, 157-167.	1.8	44
47	Decreased PCSK9 expression in human hepatocellular carcinoma. BMC Gastroenterology, 2015, 15, 176.	2.0	46
48	Exome Sequencing in Suspected Monogenic Dyslipidemias. Circulation: Cardiovascular Genetics, 2015, 8, 343-350.	5.1	45
49	Familial hypercholesterolemia mutations in the Middle Eastern and North African region: A need for a national registry. Journal of Clinical Lipidology, 2015, 9, 187-194.	1.5	44
50	A semi-automated mass spectrometric immunoassay coupled to selected reaction monitoring (MSIA–SRM) reveals novel relationships between circulating PCSK9 and metabolic phenotypes in patient cohorts. Methods, 2015, 81, 66-73.	3.8	23
51	Inflammation modulation and cardiovascular disease prevention. European Journal of Preventive Cardiology, 2015, 22, 719-733.	1.8	47
52	Severe hyperhomocysteinemia due to cystathionine \hat{l}^2 -synthase deficiency, and Factor V Leiden mutation in a patient with recurrent venous thrombosis. Thrombosis Journal, 2014, 12, 30.	2.1	4
53	The effect of insulin on circulating PCSK9 in postmenopausal obese women. Clinical Biochemistry, 2014, 47, 1033-1039.	1.9	47
54	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): Lessons Learned from Patients with Hypercholesterolemia. Clinical Chemistry, 2014, 60, 1380-1389.	3.2	32

#	Article	IF	CITATIONS
55	The <i>WWOX</i> Gene Modulates High-Density Lipoprotein and Lipid Metabolism. Circulation: Cardiovascular Genetics, 2014, 7, 491-504.	5.1	49
56	PCSK9. Circulation Research, 2014, 114, 1022-1036.	4.5	495
57	Aortic calcification: Novel insights from familial hypercholesterolemia and potential role for the low-density lipoprotein receptor. Atherosclerosis, 2013, 226, 9-15.	0.8	130
58	APOE p.Leu167del mutation in familial hypercholesterolemia. Atherosclerosis, 2013, 231, 218-222.	0.8	84
59	Regional Distribution and Metabolic Effect of PCSK9 insLEU and R46L Gene Mutations and apoE Genotype. Canadian Journal of Cardiology, 2013, 29, 927-933.	1.7	32
60	Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial. Clinical Chemistry, 2012, 58, 183-189.	3.2	133
61	The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2012, 1821, 405-415.	2.4	165
62	The LDLR deficient mouse as a model for aortic calcification and quantification by micro-computed tomography. Atherosclerosis, 2011, 219, 455-462.	0.8	54
63	Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 785-791.	2.4	220
64	High-density lipoproteins and cardiovascular disease: 2010 update. Expert Review of Cardiovascular Therapy, 2010, 8, 413-423.	1.5	31
65	Calcium Homeostasis and Skeletal Integrity in Individuals with Familial Hypercholesterolemia and Aortic Calcification. Clinical Chemistry, 2010, 56, 1599-1607.	3.2	17
66	Genetic Lipoprotein Disorders and Cardiovascular Disease., 2010,, 203-221.		0
67	Aortic calcifications in familial hypercholesterolemia: Potential role of the low-density lipoprotein receptor gene. American Heart Journal, 2009, 157, 170-176.	2.7	30
68	Acquired severe hypercholesterolemia and hypoalphalipoproteinemia. Journal of Clinical Lipidology, 2009, 3, 393-397.	1.5	3
69	Approach to the diagnosis and management of lipoprotein disorders. Current Opinion in Endocrinology, Diabetes and Obesity, 2009, 16, 132-140.	2.3	19
70	Comparison of Treatment of Severe High-Density Lipoprotein Cholesterol Deficiency in Men With Daily Atorvastatin (20 mg) Versus Fenofibrate (200 mg) Versus Extended-Release Niacin (2 g). American Journal of Cardiology, 2008, 102, 1341-1347.	1.6	21
71	Treatment of low high-density lipoprotein cholesterol. Canadian Journal of Cardiology, 2008, 24, 27C-31C.	1.7	7
72	Vascular Calcifications in Homozygote Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 777-785.	2.4	85

#	Article	IF	CITATIONS
73	Acute monoarticular arthritis caused by Maltese cross-like crystals. Cmaj, 2005, 172, 741-742.	2.0	11